Product Information

GVOKE PFS 2-PK 1 MG/0.2 ML SYR is a brand product labeled by Xeris Pharmaceuticals, Inc., priced at $1606.1900 per ML under NDC 72065013112. Its NADAC has been published 266 times since May 20, 2020.

FDA first approved this application on Sep 10, 2019.

GVOKE PFS 2-PK 1 MG/0.2 ML SYR

glucagon injection, solution
$1606.1900per ML

Strength

1 mg/.2mL

NDC

72065013112

Classification

Brand

Dosage Form

INJECTION, SOLUTION

Route

SUBCUTANEOUS

Effective Date

8/19/2026

Active Ingredients

GLUCAGON

Approval Type

New Drug (NDA)

FDA Application

NDA212097

FDA Approved

9/10/2019

On Market Since

9/10/2019

Pharmacological Classes

Antihypoglycemic Agent
Decreased GI Motility
Decreased GI Smooth Muscle Tone
Decreased Glycolysis
Gastrointestinal Motility Inhibitor
Increased Gluconeogenesis
Increased Glycogenolysis

Price Statistics

The NADAC for GVOKE PFS 2-PK 1 MG/0.2 ML SYR has been published 266 times since May 20, 2020, and over the history we have for it it has risen 19.9%. The table below summarizes its recorded NADAC range and movement.

Current price$1606.1900 per ML
All-time high$1607.2875 (Aug 12, 2026)
All-time low$1340.0286 (May 20, 2020)
52-week high$1607.2875
52-week low$1560.5036
Median price$1467.6231
Average price$1490.9352
Largest weekly change+3.0% (Feb 15, 2023)
Weeks tracked266
Tracking sinceMay 20, 2020

Price History

1W

-0.1%

1M

-0.1%

3M

-0.1%

6M

-0.1%

1Y

+2.7%

3Y

+9.4%

5Y

+19.6%

All

+19.9%

Generic Alternatives

The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 0% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.

Lowest-Cost Alternatives

Save up to 0%

1 alternative • Same active ingredient

Frequently asked questions

What is the NADAC price of GVOKE PFS 2-PK 1 MG/0.2 ML SYR?

The current National Average Drug Acquisition Cost (NADAC) for GVOKE PFS 2-PK 1 MG/0.2 ML SYR, manufactured by Xeris Pharmaceuticals, Inc., is $1606.1900 per ML (NDC 72065013112), effective Aug 19, 2026.

How has the price of GVOKE PFS 2-PK 1 MG/0.2 ML SYR changed over time?

Over the history we have for it, the NADAC for GVOKE PFS 2-PK 1 MG/0.2 ML SYR has risen 19.9%. It has been tracked across 266 weekly CMS publications since May 20, 2020.

What are the highest and lowest recorded NADAC prices for GVOKE PFS 2-PK 1 MG/0.2 ML SYR?

Since May 20, 2020, the NADAC for GVOKE PFS 2-PK 1 MG/0.2 ML SYR has ranged from a low of $1340.0286 (May 20, 2020) to a high of $1607.2875 (Aug 12, 2026), with a median of $1467.6231 per ML.

Are there cheaper alternatives to GVOKE PFS 2-PK 1 MG/0.2 ML SYR?

Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, GVOKE PFS 1-PK 1 MG/0.2 ML SYR, is $1600.2289 per ML — about 0% below GVOKE PFS 2-PK 1 MG/0.2 ML SYR.

Who manufactures GVOKE PFS 2-PK 1 MG/0.2 ML SYR?

GVOKE PFS 2-PK 1 MG/0.2 ML SYR (NDC 72065013112) is labeled by Xeris Pharmaceuticals, Inc., and CMS classifies it as a brand product.